Medicines (MDCO)  swung to a net loss for the quarter ended Sep. 30, 2014.The company has made a net loss of $16.74 million, or $ .26 a share in the quarter, against a net profit of $7.79 million, or $0.12 a share in the last year period. On the other hand, adjusted net income for the quarter stood at $11.58 million, or $0.18 a share compared with $29.29 million or $0.47 a share, a year ago.     

Revenue during the quarter went down marginally by 1.08 percent to $172.40 million from $174.28 million in the previous year period.

Total expenses were 107.34 percent of quarterly revenues, up from 86.93 percent for the same period last year.    

Operating margin for the quarter stood at negative 7.34 percent as compared to a positive 13.07 percent for the previous year period. 

Operating loss for the quarter was $12.65 million, compared with an operating income of $22.77 million in the previous year period.  

"We are making considerable and rapid progress with launches, with our ongoing NDA programs in US and Europe, and with our investigational compounds in research and development which are demonstrating impressive proof of concept in various ways as planned. These are exciting times at The Medicines Company as we build a leading acute and intensive care hospital portfolio of highly innovative new products. We expect a steady stream of news flow over the coming 3-12 months," said Clive Meanwell, Chairman and Chief Executive Officer.